PT Diagnos Laboratorium Utama Tbk (DGNS) Fair Value & Analysis
Healthcare · ID · Market cap 305B IDR
Fair value as of: Jul 16, 2026
From 22 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from 39.02 IDR to 36.31 IDR (−6.9%) since Jul 15, 2026. Share price +2.7% over the past month.
A solid business, but screening 84% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (61.19 IDR). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 129.00 IDR – 1,409 IDR · fair‑value band 35.25 IDR – 61.19 IDR · the 232.00 IDR price screens above the 36.31 IDR fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
PT Diagnos Laboratorium Utama Tbk (DGNS) currently trades at 232.00 IDR, while our model-based Fair Value estimate is 36.31 IDR, implying the stock looks roughly 84.4% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Diagnos Laboratorium Utama Tbk generated revenue of 171B IDR at a net margin of 2.0%. Revenue grew 11.9% year over year. It earns a return on equity of 1.7%. Net debt stands at 70.8B IDR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 35.25 IDR (bear case) to 61.19 IDR (bull case); at 232.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 71% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -84%, DGNS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Asset-Based (99.40 IDR) versus Growth DCF (15.89 IDR). Highest evidence: Growth DCF (80).
Notify me when DGNS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, …
Full company description
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, body fluids, feces, specific proteins, DNAnswer genomics, kidney function, liver function, immunology, osteoporosis, thyroid, pharmacogenomic, heart, reproduction and fertility, microbiology, drug monitoring, lungs, gastrointestinal, nutrition and heavy metals, anemia, and other bacteria; genomics; homecare services; and inspection panel tests. It also provides clinical pathology, anatomical pathology, and microbiology laboratory; and corporate health and research services. PT Diagnos Laboratorium Utama Tbk was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Diagnos Laboratorium Utama Tbk reported revenue of 167B IDR in FY2025 versus 302B IDR in FY2021, a compound −13.8%/yr. Reported net income was 2.9B IDR in FY2025, compounding −53.8%/yr from FY2021.
DGNS screens 84% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare PT Diagnos Laboratorium Utama Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Diagnos Laboratorium Utama Tbk (DGNS) overvalued or undervalued?
What is the fair value of DGNS?
What is the quality score of DGNS?
What is the revenue of PT Diagnos Laboratorium Utama Tbk (DGNS)?
What is the net profit margin of DGNS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Diagnos Laboratorium Utama Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.